Dr. Sibel Aydin is a Professor of Medicine at the University of Ottawa, Associate Scientist at the Ottawa Hospital Research Institute (OHRI), Director of Research at the Arthritis Centre in Ottawa, and holds a Tier 2 Research Chair in Inflammatory Arthritis.

She serves on the GRAPPA Steering Committee and is Vice President of the Canadian Rheumatology Ultrasound Society (CRUS). She is a member of several national and international initiatives, including task forces addressing difficult-to-treat disease in psoriatic arthritis and axial spondyloarthritis, and has contributed to the development of Canadian treatment recommendations for psoriatic arthritis.

Her research focuses on inflammatory arthritis, particularly psoriatic arthritis and spondyloarthritis, with an emphasis on imaging, disease phenotyping, and personalized treatment strategies. She has authored more than 180 peer-reviewed publications.

I do not have an affiliation (financial or otherwise) with any for-profit or not-for-profit organizations.

I intend to make therapeutic recommendations for medications that have not received regulatory approval (ie, “off-label” use of medications).

MD PhD FRCPC CAGF

I have/had an affiliation (financial or otherwise) with a for-profit or not-for-profit organization.
- A relationship with one or more other for-profit or not-for-profit organizations that fund this program: Celltrion
- Member of an advisory board or speakers’ bureau: Abbvie, Ferring, Takeda, J&J, Pfizer, Eli Lilly, Celltrion,
- Received payment from an organization (including gifts or other consideration, or in-kind compensation): Abbvie, Ferring, Takeda, J&J, Pfizer, Eli Lilly, Celltrion,
- Received/will receive a grant or an honorarium from a for-profit or not-for-profit organization: Abbvie, Ferring, Takeda, J&J, Pfizer, Eli Lilly, Celltrion,

I intend to make therapeutic recommendations for medications that have not received regulatory approval (ie, “off-label” use of medications).

Dr. Saloojee is a member of the Division of Gastroenterology at the Ottawa Hospital. His clinical interest is the care of patients with inflammatory bowel disease. He is part of the IBD centre of excellence at the General Hospital. His main focus is education. He is a graduate of the Distinguished Teacher Program through the University of Ottawa. He is a past co-chair of the GI block. He served as the program director for the GI residency training program for 10 years. He is currently the Program Director for the IBD fellowship program

I do not have an affiliation (financial or otherwise) with any for-profit or not-for-profit organizations.

I do not intend to make therapeutic recommendations for medications that have not received regulatory approval (ie, “off-label” use of medications).

Dr. Cynthia Seow is Professor at the Cumming School of Medicine, University of Calgary working as a Clinician Researcher in Gastroenterology. She completed internal medicine in Australia, then an Inflammatory Bowel Disease (IBD) fellowship along with a MSc in Clinical Epidemiology at the University of Toronto. Her interests include special populations, (pediatric to adult transition, sexual health, preconception and pregnancy health), pharmacokinetics of advanced therapies, and preventive care, specifically, vaccinations in IBD. Dr. Seow is the North American lead for the Global Consensus for the Management of IBD in Pregnancy and lead of the Medications in Pregnancy section; and has been involved in other international IBD pregnancy and IBD pharmacology guidelines. She maintains active research funding, has >150 peer reviewed publications, and is on several journal editorial boards. She is on the Steering Committee for Mentoring in IBD, MILESTONE Canada for IBD fellows, and faculty for MILESTONE USA, and involved in initiatives by Crohns and Colitis Canada.

I have/had an affiliation (financial or otherwise) with a for-profit or not-for-profit organization.
- Member of an advisory board or speakers’ bureau: Janssen, Abbvie, Takeda, Lilly, Ferring, Merck, Pfizer, Organon, Sandoz, Pharmascience, Fresenius Kabi, Amgen, Celltrion, Sanofi, GSK, Biocon.

I intend to make therapeutic recommendations for medications that have not received regulatory approval (ie, “off-label” use of medications).